Purple Biotech Statistics
Total Valuation
Purple Biotech has a market cap or net worth of $5.89 million. The enterprise value is -$3.59 million.
Important Dates
The next estimated earnings date is Wednesday, May 20, 2026, before market open.
| Earnings Date | May 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Purple Biotech has 1.86 billion shares outstanding. The number of shares has increased by 192.79% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.86B |
| Shares Change (YoY) | +192.79% |
| Shares Change (QoQ) | +161.42% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 18.21% |
| Float | 1.84B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.61 |
| P/TBV Ratio | 2.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 0.03.
| Current Ratio | 1.27 |
| Quick Ratio | 1.23 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -124.46% and return on invested capital (ROIC) is -20.28%.
| Return on Equity (ROE) | -124.46% |
| Return on Assets (ROA) | -15.97% |
| Return on Invested Capital (ROIC) | -20.28% |
| Return on Capital Employed (ROCE) | -71.05% |
| Weighted Average Cost of Capital (WACC) | 0.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.64M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.25% in the last 52 weeks. The beta is -0.74, so Purple Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.74 |
| 52-Week Price Change | -84.25% |
| 50-Day Moving Average | 5.06 |
| 200-Day Moving Average | 10.91 |
| Relative Strength Index (RSI) | 45.77 |
| Average Volume (20 Days) | 11,037 |
Short Selling Information
The latest short interest is 8,262, so 31.66% of the outstanding shares have been sold short.
| Short Interest | 8,262 |
| Short Previous Month | 79,903 |
| Short % of Shares Out | 31.66% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.16 |
Income Statement
| Revenue | n/a |
| Gross Profit | -59,000 |
| Operating Income | -6.98M |
| Pretax Income | -26.49M |
| Net Income | -26.39M |
| EBITDA | -6.97M |
| EBIT | -6.98M |
| Earnings Per Share (EPS) | -$0.03 |
Full Income StatementBalance Sheet
The company has $9.57 million in cash and $244,000 in debt, with a net cash position of $9.33 million or $0.01 per share.
| Cash & Cash Equivalents | 9.57M |
| Total Debt | 244,000 |
| Net Cash | 9.33M |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | 9.66M |
| Book Value Per Share | 0.01 |
| Working Capital | 2.11M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.66 million and capital expenditures -$3,000, giving a free cash flow of -$5.66 million.
| Operating Cash Flow | -5.66M |
| Capital Expenditures | -3,000 |
| Depreciation & Amortization | 3,000 |
| Net Borrowing | -217,000 |
| Free Cash Flow | -5.66M |
| FCF Per Share | -$0.00 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Purple Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -192.79% |
| Shareholder Yield | -192.79% |
| Earnings Yield | -448.16% |
| FCF Yield | -96.12% |
Analyst Forecast
The average price target for Purple Biotech is $30.00, which is 599.30% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.00 |
| Price Target Difference | 599.30% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 2, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
